Revumenib

Predictive

Supports Resistance

submitted

EID12737

Tumor DNA sequencing identified MEN1 mutations at several residues in the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting five variants identified a total of 4 patients fro… (full text at CIViC)

PMID 36922589 · Perner et al., 2023 · Open in CIViC

MEN1 G326R1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	B	Supports Resistance	3	submitted	EID12734 Tumor DNA sequencing identified the MEN1 G326R (aka G331R) variant in one patient (#2, who also had a MEN1 M322I) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting fiv… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 G326R1

Revumenib + VTP-50469Substitutes

Predictive

Supports Resistance

submitted

EID12734

Tumor DNA sequencing identified the MEN1 G326R (aka G331R) variant in one patient (#2, who also had a MEN1 M322I) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting fiv… (full text at CIViC)

PMID 36922589 · Perner et al., 2023 · Open in CIViC

MEN1 M322I1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	B	Supports Resistance	3	submitted	EID12730 Tumor DNA sequencing identified the MEN1 M322I (aka M327I) variant in two patients (#5 & 6) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting five variants identified … (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 M322I1

Revumenib + VTP-50469Substitutes

Predictive

Supports Resistance

submitted

EID12730

Tumor DNA sequencing identified the MEN1 M322I (aka M327I) variant in two patients (#5 & 6) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting five variants identified … (full text at CIViC)

PMID 36922589 · Perner et al., 2023 · Open in CIViC

MEN1 M322V1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	D	Supports Resistance	2	submitted	EID12728 Tumor DNA sequencing identified the MEN1 M322V (aka M327V) variant in two patients (#1 & 3) with KMT2A rearranged AML on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targetin… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 M322V1

Revumenib + VTP-50469Substitutes

Predictive

Supports Resistance

submitted

EID12728

Tumor DNA sequencing identified the MEN1 M322V (aka M327V) variant in two patients (#1 & 3) with KMT2A rearranged AML on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targetin… (full text at CIViC)

PMID 36922589 · Perner et al., 2023 · Open in CIViC

MEN1 Mutation1
Revumenib	Acute Leukemia	Predictive	B	Supports Resistance	4	submitted	EID12717 In follow up analyses of the AUGMENT-101 trial of revumenib in patients with acute leukemia, the authors identify MEN1 variants in bone marrow specimens obtained after treatment. These variants were n… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 Mutation1

Predictive

Supports Resistance

submitted

EID12717

In follow up analyses of the AUGMENT-101 trial of revumenib in patients with acute leukemia, the authors identify MEN1 variants in bone marrow specimens obtained after treatment. These variants were n… (full text at CIViC)

PMID 36922589 · Perner et al., 2023 · Open in CIViC

MEN1 S155T1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	C	Supports Resistance	2	submitted	EID12741 Tumor DNA sequencing identified the MEN1 S155T (aka S160T) variant in one patient (#3, who also had a MEN1 M322V) on the AUGMENT-101 phase 1 trial of Revumenib. The S155T variant was NOT detected in a… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 S155T1

Revumenib + VTP-50469Substitutes

Predictive

Supports Resistance

submitted

EID12741

Tumor DNA sequencing identified the MEN1 S155T (aka S160T) variant in one patient (#3, who also had a MEN1 M322V) on the AUGMENT-101 phase 1 trial of Revumenib. The S155T variant was NOT detected in a… (full text at CIViC)

PMID 36922589 · Perner et al., 2023 · Open in CIViC

MEN1 T344M1
Revumenib + VTP-50469Substitutes	Acute Leukemia	Predictive	B	Supports Resistance	4	submitted	EID12733 Tumor DNA sequencing identified the MEN1 T344M (aka T349M) variant in one patient (#4) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting five variants identified a tot… (full text at CIViC) PMID 36922589 · Perner et al., 2023 · Open in CIViC	civic

MEN1 T344M1

Revumenib + VTP-50469Substitutes

Predictive

Supports Resistance

submitted

EID12733

Tumor DNA sequencing identified the MEN1 T344M (aka T349M) variant in one patient (#4) on the AUGMENT-101 phase 1 trial of Revumenib. An additional ddPCR assay targeting five variants identified a tot… (full text at CIViC)

PMID 36922589 · Perner et al., 2023 · Open in CIViC

NPM1 MUTATION1
Revumenib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	submitted	EID12743 Results from phase II of the AUGMENT-101 trial are reported for patients with NPM1 mutant relapsed/refractory AML (≥3 previous lines of therapy) treated with revumenib. Patients received revumenib wit… (full text at CIViC) PMID 40332046 · Arellano et al., 2025 · Open in CIViC	civic

NPM1 MUTATION1

Acute Myeloid LeukemiaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID12743

Results from phase II of the AUGMENT-101 trial are reported for patients with NPM1 mutant relapsed/refractory AML (≥3 previous lines of therapy) treated with revumenib. Patients received revumenib wit… (full text at CIViC)

PMID 40332046 · Arellano et al., 2025 · Open in CIViC

IDH1 Mutation + IDH2 Mutation + NPM1 MUTATIONIDH2 IDH1 NPM11
Revumenib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID12744 Results from phase II of the AUGMENT-101 trial are reported for patients with NPM1 mutant relapsed/refractory AML (≥3 previous lines of therapy) treated with revumenib. Patients received revumenib wit… (full text at CIViC) PMID 40332046 · Arellano et al., 2025 · Open in CIViC	civic

IDH1 Mutation + IDH2 Mutation + NPM1 MUTATIONIDH2 IDH1 NPM11

Acute Myeloid LeukemiaCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID12744

PMID 40332046 · Arellano et al., 2025 · Open in CIViC

NPM1 EXON 11 MUTATION1
Revumenib	Acute Myeloid Leukemia with NPM1 MutationALIAS	Predictive	B	Supports Sensitivity Response	4	submitted	EID13286 In the phase 2 portion of AUGMENT-101 (NCT04065399), an open-label, single-arm, multicentre study, patients with relapsed or refractory NPM1-mutated acute myeloid leukaemia received the oral menin inh… (full text at CIViC) PMID 40332046 · Arellano et al., 2025 · Open in CIViC	civic

NPM1 EXON 11 MUTATION1

Acute Myeloid Leukemia with NPM1 MutationALIAS

Predictive

Supports Sensitivity Response

submitted

EID13286

In the phase 2 portion of AUGMENT-101 (NCT04065399), an open-label, single-arm, multicentre study, patients with relapsed or refractory NPM1-mutated acute myeloid leukaemia received the oral menin inh… (full text at CIViC)

PMID 40332046 · Arellano et al., 2025 · Open in CIViC